6450 Lusk Blvd. Suite E202
San Diego, CA 92121
Veriskin, Inc. is a medical device startup focusing on developing a noninvasive device for skin cancer screening. Skin cancer is the most common form of cancer in the US, accounting for just under half of all cancers or 3.5 million diagnoses annually. An estimated $5.8 billion is spent on dermatology visits and skin biopsies each year to determine whether a suspect skin lesion is cancerous or not. VeriSkin has developed a novel, low-cost, inexpensive method and handheld device for non-invasive skin cancer diagnostic which determines if a suspect skin growth is cancerous in ~ 1 min. We have demonstrated an unparalleled 100% sensitivity and 96.7% specificity in discriminating skin cancers from benign skin growths in recent clinical studies performed in multiple dermatology clinics in CA and AZ. Anticipated savings to the US healthcare industry and insurers are estimated at $3.2B through reduction of unnecessary biopsies and referrals to dermatologists. In 2016 Veriskin, Inc. has been awarded a SBIR Phase II grant award by the National Cancer Institute of the NIH.